Evidence map›Paper›PMID 26316797›Full record

ArticleInternational journal of nephrology and renovascular disease2015

Elevation of urinary liver-type fatty acid binding protein after cardiac catheterization related to cardiovascular events.

Atsuko Kamijo-Ikemori, Nobuyuki Hashimoto, Takeshi Sugaya, Katsuomi Matsui, Mikako Hisamichi, Yugo Shibagaki, Fumihiko Miyake, Kenjiro Kimura

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nephrology and renovascular disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04864847 (A Study of Contrast-induced Acute Kidney Injury Prediction Using the RENISCHEM L-FABP Assay at the Point-of-Care), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04864847 completednot on this mapstarted 2021, after this paper: background citation

A Study of Contrast-induced Acute Kidney Injury Prediction Using the RENISCHEM L-FABP Assay at the Point-of-Care

TypeobservationalSponsorHikari Dx, Inc.Ran2021 to 2026Enrolled382ConditionsAcute Kidney Injury, Contrast-induced NephropathyArmsRENISCHEM L-FABP POC Test
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Atsuko Kamijo-IkemoriDepartment of Nephrology and Hypertension, St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan ; Department of Anatomy, St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Nobuyuki HashimotoDepartment of Cardiology, St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Takeshi SugayaDepartment of Nephrology and Hypertension, St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Katsuomi MatsuiDepartment of Nephrology and Hypertension, St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Mikako HisamichiDepartment of Nephrology and Hypertension, St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Yugo ShibagakiDepartment of Nephrology and Hypertension, St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Fumihiko MiyakeDepartment of Cardiology, St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Kenjiro KimuraDepartment of Nephrology and Hypertension, St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Hypertension Institute · USSt. Marianna University School of Medicine · JPInstitute of Cardiology · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeContrast medium (CM) induces tubular hypoxia via endothelial damage due to direct cytotoxicity or viscosity. Urinary liver-type fatty acid binding protein (L-FABP) increases along with tubular hypoxia and may be a detector of systemic circulation injury. The aim of this study was to evaluate the clinical usefulness of detecting increases in urinary L-FABP levels due to administration of CM, as a prognostic biomarker for cardiovascular disease in patients without occurrence of CM-induced nephropathy undergoing cardiac catheterization procedure (CCP).

methodsRetrospective longitudinal analyses of the relationship between urinary L-FABP levels and occurrence of cardiovascular events were performed (n=29). Urinary L-FABP was measured by ELISA before CCP, and at 6, 12, 24, and 48 hours after CCP.

resultsUrinary L-FABP levels were significantly higher at 12 hours (P<0.05) and 24 hours (P<0.005) after CCP compared with before CCP, only in the patients with occurrence of cardiovascular events (n=17), but not in those without cardiovascular events (n=12). The parameter with the largest area under the curve (0.816) for predicting the occurrence of cardiovascular events was the change in urinary L-FABP at 24 hours after CCP. The difference in urinary L-FABP levels (ΔL-FABP ≥11.0 μg/g creatinine) between before CCP and at 24 hours after CCP was a risk factor for the occurrence of cardiovascular events (hazard ratio, 4.93; 95% confidence interval, 1.27-19.13; P=0.021).

conclusionMeasurement of urinary L-FABP before CCP and at 24 hours after CCP in patients with mild to moderate renal dysfunction may be an important indicator for risk stratification of onset of cardiovascular events.

Indexed as

cardiovascular eventchronic kidney diseasecontrast mediumL-FABPrenal dysfunctionurinary biomarkerurinary liver-type fatty acid binding protein

Identifiers

PMID26316797
PMCPMC4547648
OpenAlexW1545324235

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.